Specialty Pharmacy

Beta-blockers found reduce to stress from hormones that fuel disease progression.

Study may help improve early cancer detection.

Researchers evaluate the benefits of subcutaneous methotrexate compared with the oral version.

Higher levels of physical activities leads to lower MS relapse rates.

Amgen is seeking FDA approval for etelcalcetide, the first calcimimetic agent administered intravenously after dialysis to treat secondary hyperparathyroidism in patients with chronic kidney disease.

An independent pharmacy will pay a $46,000 settlement over an alleged lack of break times for its employees.

Study estimates United States is wasting $45 million every month that biosimilar Zarxio is not on the market.

Top stories of the week on Specialty Pharmacy Times.

Findings may better predict organ rejection before transplantation.

Researchers target the spread of diseases such as HIV, SARS, and Ebola.

Pharmacists must prepare for full enforcement of the Drug Supply Chain Security Act (DSCSA) in order to avoid significant penalties associated with noncompliance.

Highly effective cholesterol-lowering drug to challenge Regeneron & Sanofi's Praluent.

Blocking oxygen sensor may improve colorectal cancer treatment.

Treatment has complementary actions that help control blood glucose.

Cancer drug may benefit patients with specific genetic mutation.

Researchers evaluate how PTEN protein regulates cell growth and how mutations can lead to cancer.

Nano sensor able to catch MS in early development.

Data tracking may someday become a key component in limiting disease spread.

Cabozantinib is a potential treatment for patients with advanced renal cell carcinoma who received one prior therapy.

Researchers shed light on association between alcohol consumption and cancer.

Two different dose prescriptions achieve similar results.

Doppler system correctly identified 100% of patients with malignant skin cancer.

Cancer drug significantly reduces the risk for clinically relevant non-major bleeding.

Promacta use now includes young children with chronic immune thrombocytopenia.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.

Findings could lead to more effective treatments for diseases such as cancer and multiple sclerosis.

Treatment seeks to teach the immune system to ignore a peptide that leads to inflammation.

New cancer detection technique may reduce the need for costly low-dose CT scans.